Health Care • Biotechnology: Pharmaceutical Preparations
$17.29 ▼ -1.00
(-5.47%)
MKT CAP: $875.7M • VOL: 1.04M
52W L $8 52W H $19
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$15
MEDIAN
$19
MEAN
$20
HIGH
$24
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CYRX TAPE
CYRX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $20.92 | $19.88 | 2025-02-14 | $15.73 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $21.79 | $20.40 | 2025-02-06 | $16.25 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $19.71 | $19.02 | 2025-01-29 | $16.60 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $17.64 | — | 2025-01-17 | $16.94 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $15.22 | $16.43 | 2025-01-09 | $15.39 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $20.58 | $17.98 | 2024-12-18 | $15.04 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $16.77 | $17.46 | 2024-12-04 | $16.08 | -4.3% | 48% | C |